Catalent Pharma Solutions today announced that they will be presenting at the upcoming CASSS WCBP Symposium on Jan 30 – Feb 1, 2018.
SOMERSET, N.J. – January 29, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Mike Merges, Director of Strategic Growth of Biologics Analytical Services and Mike Sadick, Ph.D., Principal Scientist, Biologics Analytical Services, will be presenting at the upcoming CASSS WCBP Symposium, to be held at The Mayflower Hotel, Washington DC, on Jan 30 – Feb 1, 2018.
The presentation, on Tuesday, Jan 30 at 1 p.m., is entitled “New Directions in Cell Banking and Assay Automation,” and will discuss the process of developing and optimizing the capacity of analytical cell banks, as well as the application of automation to ELISA, bioassay preparation and execution. Focusing on first-hand experience in undertaking these activities, the speakers will highlight how the large number of different types of cell and cell lines presents a challenge, as each one will often have specific needs and characteristics. The presentation will also look at the strategies, and lessons learned, from installing equipment/instrumentation to adapt assays – ELISA, bioassay and molecular – to automated strategies.
For more information on the symposium, visit casss.org/WCBP2018
Dr. Sadick has an extensive background in cellular biology, cellular immunology, receptor signaling, molecular biology and biochemistry. He has more than 30 years’ experience in research and industry, having held positions at Genentech, Eli Lilly and Aptuit before joining Catalent in 2012. His current role sees him lead Catalent’s activities in potency assays, both cell-based and enzyme-linked immunosorbent assay (ELISA) based, as well as molecular biology (including cloning and quantitative polymerase chain reaction (qPCR)), and protein/protein binding assessment. He holds a bachelor’s degree in biology from John Hopkins University, and a master’s degree and doctorate, both in immunology, from the University of Washington.
Mr. Merges joined Catalent in 2011 as Director of Catalent Biologics Analytical Services, focusing on the transfer, development, validation, and performance of bioassays, immunoassays, microbiological assays, and viral clearance assays. Before that, he was Associate Director of Bioservices for Lonza Biologics, and has also held positions at the University of Maryland’s Institute of Human Virology, the National Cancer Institute and Johns Hopkins University, where he conducted viral immunology research. He obtained his bachelor’s degree in microbiology from the Pennsylvania State University, and his master’s degree in microbiology/virology from Hood College.
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com